Matrix Metalloproteinase Responsive Delivery of Myostatin Inhibitors
- 645 Downloads
The inhibition of myostatin - a member of the transforming growth factor (TGF–β) family - drives regeneration of functional skeletal muscle tissue. We developed a bioresponsive drug delivery system (DDS) linking release of a myostatin inhibitor (MI) to inflammatory flares of myositis to provide self-regulated MI concentration gradients within tissues of need.
A protease cleavable linker (PCL) – responding to MMP upregulation – is attached to the MI and site-specifically immobilized on microparticle surfaces.
The PCL disintegrated in a matrix metalloproteinase (MMP) 1, 8, and particularly MMP-9 concentration dependent manner, with MMP-9 being an effective surrogate biomarker correlating with the activity of myositis. The bioactivity of particle-surface bound as well as released MI was confirmed by luciferase suppression in stably transfected HEK293 cells responding to myostatin induced SMAD phosphorylation.
We developed a MMP-responsive DDS for MI delivery responding to inflammatory flare of a diseased muscle matching the kinetics of MMP-9 upregulation, with MMP-9 kinetics matching (patho-) physiological myostatin levels.
KEY WORDSbioorthogonal chemistry bioresponsive drug delivery controlled release myostatin protease cleavable linker
Activin receptor IIB
Bovine serum albumin
Copper(I)-catalyzed azide-alkyne cycloaddition
Drug delivery system
Duchenne muscular dystrophy
Growth differentiation factor 8
High-performance liquid chromatography
Insulin-like growth factor I
Matrix-assisted laser desorption ionization mass spectrometry
Myosin heavy chain
Nuclear factor-kappa B
Protease cleavable linker
Relative light unit
Real time polymerase chain reaction
SMAD binding element
Strain-promoted azide-alkyne cycloaddition
Solid phase peptide synthesis
Transglutaminase (human, fXIIIa)
Transforming growth factor beta
Tumor necrosis factor α
ACKNOWLEDGMENTS AND DISCLOSURES
We thank Petra Knaus (Freie Universität Berlin, Germany) for providing us with the pGl3ti-SBE constructs and Melanie Krug for excellent technical assistance. We thank Dr. Joachim Nickel for providing C2C12 myoblast cells. The financial support of the Bavarian research foundation (grant # AZ-1044-12 ‘FORMOsA’) and the Deutsche Forschungsgemeinschaft (DFG; ME 3820/3-1) are gratefully acknowledged. H.G. is full time associate of Gilyos GmbH.
- 11.Latres E, Pangilinan J, Miloscio L, Bauerlein R, Na E, Potocky TB, et al. Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice. Skelet Muscle. 2015;5.Google Scholar
- 12.Han H, Min H, Boone TC, inventors; Amgen Inc, assignee. Binding agents which inhibit myostatin patent #1581649, Priority claimed as of 20.12.02/USP435923. Apr 19 2011.Google Scholar
- 14.Fukushima K, Nakamura A, Ueda H, Yuasa K, Yoshida K, Takeda Si, et al. Activation and localization of matrix metalloproteinase-2 and-9 in the skeletal muscle of the muscular dystrophy dog (CXMDJ). Bmc Musculoskeletal Disorders. 2007;8.Google Scholar
- 19.Lutolf MP, Lauer-Fields JL, Schmoekel HG, Metters AT, Weber FE, Fields GB, et al. Synthetic matrix metalloproteinase-sensitive hydrogels for the conduction of tissue regeneration: engineering cell-invasion characteristics. Proc Natl Acad Sci U S A. 2003;100(9):5413–8.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Steinhagen M, Hoffmeister P-G, Nordsieck K, Hoetzel R, Baumann L, Hacker MC, et al. Matrix metalloproteinase 9 (MMP-9) mediated release of MMP-9 resistant stromal cell-derived factor 1 alpha (SDF-1 alpha) from surface modified polymer films. ACS Appl Mater Interfaces. 2014;6(8):5891–9.CrossRefPubMedGoogle Scholar
- 34.Jonk LJC, Itoh S, Heldin CH, ten Dijke P, Kruijer W. Identification and functional characterization of a Smad binding element (SBE) in the JunB promoter that acts as a transforming growth factor-beta, activin, and bone morphogenetic protein-inducible enhancer. J Biol Chem. 1998;273(33):21145–52.CrossRefPubMedGoogle Scholar
- 47.Bursac N, Juhas M, Rando TA. Synergizing engineering and biology to treat and model skeletal muscle injury and disease. In: Yarmush ML, editor. Annual review of biomedical engineering, Vol 17. Annual Review of Biomedical Engineering. 172015. p. 217–42.Google Scholar